Editas Medicine Inc (EDIT) concluded trading on Wednesday at a closing price of $2.56, with 9.52 million shares of worth about $24.36 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 111.57% during that period and on July 02, 2025 the price saw a gain of about 13.78%. Currently the company’s common shares owned by public are about 83.71M shares, out of which, 82.95M shares are available for trading.
Stock saw a price change of 16.89% in past 5 days and over the past one month there was a price change of 44.63%. Year-to-date (YTD), EDIT shares are showing a performance of -45.18% which increased to 101.57% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.91 but also hit the highest price of $6.05 during that period. The average intraday trading volume for Editas Medicine Inc shares is 2.20 million. The stock is currently trading 20.30% above its 20-day simple moving average (SMA20), while that difference is up 42.71% for SMA50 and it goes to 27.45% higher than SMA200.
Editas Medicine Inc (NASDAQ: EDIT) currently have 83.71M outstanding shares and institutions hold larger chunk of about 54.28% of that.
The stock has a current market capitalization of $214.30M and its 3Y-monthly beta is at 2.18. It has posted earnings per share of -$3.04 in the same period. It has Quick Ratio of 3.08 while making debt-to-equity ratio of 0.50. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EDIT, volatility over the week remained 12.54% while standing at 11.96% over the month.
Stock’s fiscal year EPS is expected to rise by 34.40% while it is estimated to increase by 42.87% in next year. EPS is likely to grow at an annualized rate of 27.74% for next 5-years, compared to annual growth of -1.48% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on April 28, 2025 offering a Buy rating for the stock and assigned a target price of $3 to it. On December 13, 2024, Truist Downgrade their recommendations, while on December 13, 2024, Stifel Downgrade their ratings for the stock with a price target of $3. Stock get a Neutral rating from Chardan Capital Markets on December 13, 2024.
